moderna merck - Search News

Merck and Moderna, melanoma

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.

· 3d

Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

· 2d

A vaccine for melanoma recurrence? Merck, Moderna say trial promising

· 6h

Investors Thought Moderna Was Left for Dead. Then Came a Cancer Breakthrough.

After years of contending with steep stock drops, cash burn and political headwinds, Moderna delivered the kind of triumph biotech startups rarely enjoy twice.

· 1d

Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

· 1d

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

· 8h

Health Care Up as Moderna Leads Biotech Higher - Health Care Roundup

Moderna shares rose 9% as a breakthrough in skin-cancer vaccines, divulged earlier this week, continued to stoke investor excitement.

· 1d

Moderna’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

· 1d

From COVID to cancer: How Moderna’s stock jumped 177% in a day

BioSpace

Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal

Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.

Medical Marketing & Media

Rx Rundown: Moderna, Merck, LEO Pharma and more

The Food and Drug Administration granted accelerated approval to Zenbexus, or iberdomide, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for certain adults with previously treated multiple myeloma. The drug is made by Bristol Myers Squibb.

1don MSN

Melanoma kills 8,500 Americans a year. An mRNA vaccine may help stop it from coming back.

Moderna and Merck are advancing an experimental mRNA vaccine aimed at preventing melanoma — the deadliest form of skin cancer — from returning after surgery, with FDA approval sought for next year.

BioSpace

Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future

Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.